Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis

Cytokine and Growth Factor Reviews

Volumn 22, Issue 4, 2011, Pages 197-210

  Olière, Stéphanie ^a,b   Douville, Renée ^a   Sze, Alexandre ^a,b   Belgnaoui, S Mehdi ^a,b   Hiscott, John ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

Adult T cell leukemia; Gene expression; HTLV 1; Innate immunity; Interferon; Pattern recognition receptors

Indexed keywords

2 5A; ANTIVIRUS AGENT; BORTEZOMIB; GROWTH FACTOR; GSK 983; HISTONE DEACETYLASE INHIBITOR; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ADAPTIVE IMMUNITY; ASYMPTOMATIC INFECTION; DISEASE COURSE; GENE EXPRESSION; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; T CELL LEUKEMIA; TROPICAL SPASTIC PARAPARESIS; UPREGULATION; VIRUS CARRIER; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNITY, INNATE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; OPPORTUNISTIC INFECTIONS; PARAPARESIS, TROPICAL SPASTIC; RECEPTORS, PATTERN RECOGNITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 81155123130     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.08.002     Document Type: Review

References (163)

1. Bangham C.R., Meekings K., Toulza F., Nejmeddine M., Majorovits E., Asquith B., et al. The immune control of HTLV-1 infection: selection forces and dynamics. Front Biosci 2009, 14:2889-2903.
2. Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci 2007, 98:772-778.
3. Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
4. Yakova M., Lezin A., Dantin F., Lagathu G., Olindo S., Jean-Baptiste G., et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005, 2:4.
5. Verdonck K., Gonzalez E., Van Dooren S., Vandamme A.M., Vanham G., Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7:266-281.
6. Mahieux R., Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009, 57:161-166.
7. Poiesz B.J., Poiesz M.J., Choi D. The human T-cell lymphoma/leukemia viruses. Cancer Invest 2003, 21:253-277.
8. Journo C., Douceron E., Mahieux R. HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol 2009, 4:425-440.
9. Nagai M., Brennan M.B., Sakai J.A., Mora C.A., Jacobson S. CD8(+) cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 2001, 98:1858-1861.
10. Jones K.S., Petrow-Sadowski C., Huang Y.K., Bertolette D.C., Ruscetti F.W. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008, 14:429-436.
11. Manel N., Battini J.L., Taylor N., Sitbon M. HTLV-1 tropism and envelope receptor. Oncogene 2005, 24:6016-6025.
12. Manel N., Kim F.J., Kinet S., Taylor N., Sitbon M., Battini J.L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115:449-459.
13. Pinon J.D., Klasse P.J., Jassal S.R., Welson S., Weber J., Brighty D.W., et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003, 77:9922-9930.
14. Jones K.S., Petrow-Sadowski C., Bertolette D.C., Huang Y., Ruscetti F.W. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 2005, 79:12692-12702.
15. Ghez D., Lepelletier Y., Lambert S., Fourneau J.M., Blot V., Janvier S., et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol 2006, 80:6844-6854.
16. Lambert S., Bouttier M., Vassy R., Seigneuret M., Petrow-Sadowski C., Janvier S., et al. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood 2009, 113:5176-5185.
17. Mazurov D., Ilinskaya A., Heidecker G., Lloyd P., Derse D. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog 2010, 6:e1000788.
18. Pais-Correia A.M., Sachse M., Guadagnini S., Robbiati V., Lasserre R., Gessain A., et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16:83-89.
19. Van Prooyen N., Gold H., Andresen V., Schwartz O., Jones K., Ruscetti F., et al. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc Natl Acad Sci USA 2010, 107:20738-20743.
20. Van Prooyen N., Andresen V., Gold H., Bialuk I., Pise-Masison C., Franchini G. Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins. Mol Aspects Med 2010, 31:333-343.
21. Gillet N.A., Malani N., Melamed A., Gormley N., Carter R., Bentley D., et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 2011, 117:3113-3122.
22. Gaudray G., Gachon F., Basbous J., Biard-Piechaczyk M., Devaux C., Mesnard J.M. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002, 76:12813-12822.
23. Larocca D., Chao L.A., Seto M.H., Brunck T.K. Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem Biophys Res Commun 1989, 163:1006-1013.
24. Burton M., Upadhyaya C.D., Maier B., Hope T.J., Semmes O.J. Human T-cell leukemia virus type 1 Tax shuttles between functionally discrete subcellular targets. J Virol 2000, 74:2351-2364.
25. Matsuoka M., Jeang K.T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
26. Boxus M., Twizere J.C., Legros S., Dewulf J.F., Kettmann R., Willems L. The HTLV-1 Tax interactome. Retrovirology 2008, 5:76.
27. Xie L., Yamamoto B., Haoudi A., Semmes O.J., Green P.L. PDZ binding motif of HTLV-1 Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo. Blood 2006, 107:1980-1988.
28. Vendel A.C., McBryant S.J., Lumb K.J. KIX-mediated assembly of the CBP-CREB-HTLV-1 tax coactivator-activator complex. Biochemistry 2003, 42:12481-12487.
29. Yao J., Wigdahl B. Human T cell lymphotropic virus type I genomic expression and impact on intracellular signaling pathways during neurodegenerative disease and leukemia. Front Biosci 2000, 5:D138-D168.
30. Gitlin S.D., Dittmer J., Shin R.C., Brady J.N. Transcriptional activation of the human T-lymphotropic virus type I long terminal repeat by functional interaction of Tax1 and Ets1. J Virol 1993, 67:7307-7316.
31. Harrod R., Kuo Y.L., Tang Y., Yao Y., Vassilev A., Nakatani Y., et al. p300 and p300/cAMP-responsive element-binding protein associated factor interact with human T-cell lymphotropic virus type-1 Tax in a multi-histone acetyltransferase/activator-enhancer complex. J Biol Chem 2000, 275:11852-11857.
32. Matsuoka M., Jeang K.T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011, 30:1379-1389.
33. Kfoury Y., Setterblad N., El-Sabban M., Zamborlini A., Dassouki Z., El Hajj H., et al. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood 2011, 117:190-199.
34. Kfoury Y., Nasr R., Favre-Bonvin A., El-Sabban M., Renault N., Giron M.L., et al. Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. Oncogene 2008, 27:1665-1676.
35. Durkin S.S., Ward M.D., Fryrear K.A., Semmes O.J. Site-specific phosphorylation differentiates active from inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem 2006, 281:31705-31712.
36. Kashanchi F., Brady J.N. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene 2005, 24:5938-5951.
37. Kusuhara K., Anderson M., Pettiford S.M., Green P.L. Human T-cell leukemia virus type 2 Rex protein increases stability and promotes nuclear to cytoplasmic transport of gag/pol and env RNAs. J Virol 1999, 73:8112-8119.
38. Younis I., Green P.L. The human T-cell leukemia virus Rex protein. Front Biosci 2005, 10:431-445.
39. Cavanagh M.H., Landry S., Audet B., Arpin-Andre C., Hivin P., Pare M.E., et al. HTLV-I antisense transcripts initiating in the 3'LTR are alternatively spliced and polyadenylated. Retrovirology 2006, 3:15.
40. Hivin P., Frederic M., Arpin-Andre C., Basbous J., Gay B., Thebault S., et al. Nuclear localization of HTLV-I bZIP factor (HBZ) is mediated by three distinct motifs. J Cell Sci 2005, 118:1355-1362.
41. Arnold J., Yamamoto B., Li M., Phipps A.J., Younis I., Lairmore M.D., et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006, 107:3976-3982.
42. Lemasson I., Lewis M.R., Polakowski N., Hivin P., Cavanagh M.H., Thebault S., et al. Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J Virol 2007, 81:1543-1553.
43. Matsuoka M. HTLV-1 bZIP factor gene: its roles in HTLV-1 pathogenesis. Mol Aspects Med 2010.
44. Barbeau B., Mesnard J.M. Does the HBZ gene represent a new potential target for the treatment of adult T-cell leukemia?. Int Rev Immunol 2007, 26:283-304.
45. Basbous J., Arpin C., Gaudray G., Piechaczyk M., Devaux C., Mesnard J.M. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 2003, 278:43620-43627.
46. Arnold J., Zimmerman B., Li M., Lairmore M.D., Green P.L. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 2008, 112:3788-3797.
47. Bindhu M., Nair A., Lairmore M.D. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci 2004, 9:2556-2576.
48. Yasunaga J., Matsuoka M. Leukaemogenic mechanism of human T-cell leukaemia virus type I. Rev Med Virol 2007, 17:301-311.
49. Ghorbel S., Sinha-Datta U., Dundr M., Brown M., Franchini G., Nicot C. Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit. J Biol Chem 2006, 281:37150-37158.
50. Bai X.T., Baydoun H.H., Nicot C. HTLV-I p30: a versatile protein modulating virus replication and pathogenesis. Mol Aspects Med 2010, 31:344-349.
51. Biasiotto R., Aguiari P., Rizzuto R., Pinton P., D'Agostino D.M., Ciminale V. The p13 protein of human T cell leukemia virus type 1 (HTLV-1) modulates mitochondrial membrane potential and calcium uptake. Biochim Biophys Acta 2010, 1797:945-951.
52. Silic-Benussi M., Marin O., Biasiotto R., D'Agostino D.M., Ciminale V. Effects of human T-cell leukemia virus type 1 (HTLV-1) p13 on mitochondrial K+ permeability: a new member of the viroporin family?. FEBS Lett 2010, 584:2070-2075.
53. Andresen V., Pise-Masison C.A., Sinha-Datta U., Bellon M., Valeri V., Washington Parks R., et al. Suppression of HTLV-1 replication by Tax-mediated re-routing of the p13 viral protein to nuclear speckles. Blood 2011.
54. Taylor J.M., Brown M., Nejmeddine M., Kim K.J., Ratner L., Lairmore M., et al. Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. J Virol 2009, 83:11467-11476.
55. Nicot C., Mulloy J.C., Ferrari M.G., Johnson J.M., Fu K., Fukumoto R., et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001, 98:823-829.
56. Ding W., Kim S.J., Nair A.M., Michael B., Boris-Lawrie K., Tripp A., et al. Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation. J Virol 2003, 77:11027-11039.
57. Takeuchi O., Akira S. Innate immunity to virus infection. Immunol Rev 2009, 227:75-86.
58. Yoneyama M., Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 2010, 20:4-22.
59. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
60. Bell J.K., Askins J., Hall P.R., Davies D.R., Segal D.M. The dsRNA binding site of human Toll-like receptor 3. Proc Natl Acad Sci USA 2006, 103:8792-8797.
61. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
62. Shi Z., Cai Z., Sanchez A., Zhang T., Wen S., Wang J., et al. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011, 286:4517-4524.
63. Yoneyama M., Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008, 29:178-181.
64. Malathi K., Dong B., Gale M., Silverman R.H. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007, 448:816-819.
65. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008, 205:1601-1610.
66. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
67. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
68. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6:981-988.
69. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
70. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 2007, 282:15325-15329.
71. Onomoto K., Yoneyama M., Fujita T. Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr Top Microbiol Immunol 2007, 316:193-205.
72. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
73. Yang P., An H., Liu X., Wen M., Zheng Y., Rui Y., et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 2010, 11:487-494.
74. Hiscott J. Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev 2007, 18:483-490.
75. Grandvaux N., tenOever B.R., Servant M.J., Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002, 15:259-267.
76. Solis M., Goubau D., Romieu-Mourez R., Genin P., Civas A., Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol 2006, 72:1469-1476.
77. Douville R.N., Hiscott J. The interface between the innate interferon response and expression of host retroviral restriction factors. Cytokine 2010.
78. Randall R.E., Goodbourn S. Interferons viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
79. Saito T., Gale M. Principles of intracellular viral recognition. Curr Opin Immunol 2007, 19:17-23.
80. Colisson R., Barblu L., Gras C., Raynaud F., Hadj-Slimane R., Pique C., et al. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010, 115:2177-2185.
81. Kane M., Case L.K., Wang C., Yurkovetskiy L., Dikiy S., Golovkina T.V. Innate immune sensing of retroviral infection via toll-like receptor 7 occurs upon viral entry. Immunity 2011, 35:135-145.
82. Vendrame D., Sourisseau M., Perrin V., Schwartz O., Mammano F. Partial inhibition of HIV replication by Type-I interferons: impact of cell-to-cell viral transfer. J Virol 2009.
83. Hou W., Wang X., Ye L., Zhou L., Yang Z.Q., Riedel E., et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009, 83:3834-3842.
84. Adalid-Peralta L., Godot V., Colin C., Krzysiek R., Tran T., Poignard P., et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008, 83:1060-1067.
85. Kinpara S., Hasegawa A., Utsunomiya A., Nishitsuji H., Furukawa H., Masuda T., et al. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol 2009, 83:5101-5108.
86. Mahieux R., Hermine O. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha. Leuk Lymphoma 2005, 46:347-355.
87. Hishizawa M., Imada K., Kitawaki T., Ueda M., Kadowaki N., Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol 2004, 125:568-575.
88. Beignon A.S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavanagh D.G., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005, 115:3265-3275.
89. Hall W.W., Fujii M. Deregulation of cell-signaling pathways in HTLV-1 infection. Oncogene 2005, 24:5965-5975.
90. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001, 19:475-496.
91. Hiscott J., Nguyen T.L., Arguello M., Nakhaei P., Paz S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006, 25:6844-6867.
92. Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 2001, 20:6805-6815.
93. O'Mahony A.M., Montano M., Van Beneden K., Chen L.F., Greene W.C. Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem 2004, 279:18137-18145.
94. Zhao T., Yasunaga J., Satou Y., Nakao M., Takahashi M., Fujii M., et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009, 113:2755-2764.
95. Isono O., Ohshima T., Saeki Y., Matsumoto J., Hijikata M., Tanaka K., et al. Human T-cell leukemia virus type 1 HBZ protein bypasses the targeting function of ubiquitination. J Biol Chem 2008, 283:34273-34282.
96. Bouzar A.B., Willems L. How HTLV-1 may subvert miRNAs for persistence and transformation. Retrovirology 2008, 5:101.
97. Bellon M., Lepelletier Y., Hermine O., Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 2009, 113:4914-4917.
98. Pichler K., Schneider G., Grassmann R. MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 2008, 5:100.
99. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007, 179:5082-5089.
100. Hou J., Wang P., Lin L., Liu X., Ma F., An H., et al. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 2009, 183:2150-2158.
101. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006, 103:12481-12486.
102. Tomita M., Tanaka Y., Mori N. MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-1-infected T-cells. Int J Cancer 2009.
103. Feng X., Ratner L. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology 2008, 374:210-216.
104. Zhang J., Yamada O., Kawagishi K., Araki H., Yamaoka S., Hattori T., et al. Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. Virology 2008, 379:306-313.
105. Charoenthongtrakul S., Zhou Q., Shembade N., Harhaj N.S., Harhaj E.W. Human T Cell Leukemia Virus Type 1 Tax Inhibits Innate Antiviral Signaling via NF-{kappa}B-Dependent Induction of SOCS1. J Virol 2011, 85:6955-6962.
106. Oliere S., Hernandez E., Lezin A., Arguello M., Douville R., Nguyen T.L., et al. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 2010, 6:e1001177.
107. Dimitriou I.D., Clemenza L., Scotter A.J., Chen G., Guerra F.M., Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev 2008, 224:265-283.
108. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
109. Lanier L.L. NK cell recognition. Ann Rev Immunol 2005, 23:225-274.
110. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
111. Banerjee P., Feuer G., Barker E. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. J Virol 2007, 81:9707-9717.
112. Matsuura E., Yamano Y., Jacobson S. Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol 2010, 5:310-325.
113. Bangham C.R. CTL quality and the control of human retroviral infections. Eur J Immunol 2009, 39:1700-1712.
114. Croda M.G., de Oliveira A.C., Vergara M.P., Bonasser F., Smid J., Duarte A.J., et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci 2008, 269:133-137.
115. Ishitsuka K., Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 2008, 80:185-196.
116. Goncalves D.U., Proietti F.A., Ribas J.G., Araujo M.G., Pinheiro S.R., Guedes A.C., et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010, 23:577-589.
117. Yasunaga J., Matsuoka M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 2007, 14:133-140.
118. Migone T.S., Lin J.X., Cereseto A., Mulloy J.C., O'Shea J.J., Franchini G., et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995, 269:79-81.
119. Azimi N., Jacobson S., Leist T., Waldmann T.A. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 1999, 163:4064-4072.
120. Grassmann R., Aboud M., Jeang K.T. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005, 24:5976-5985.
121. Peloponese J.M., Kinjo T., Jeang K.T. Human T-cell leukemia virus type 1 Tax and cellular transformation. Int J Hematol 2007, 86:101-106.
122. Giam C.Z., Jeang K.T. HTLV-1 Tax and adult T-cell leukemia. Frontiers Biosci J Virt Library 2007, 12:1496-1507.
123. Peloponese J.M., Yeung M.L., Jeang K.T. Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation. Immunol Res 2006, 34:1-12.
124. Marriott S.J., Semmes O.J. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005, 24:5986-5995.
125. Franchini G., Nicot C., Johnson J.M. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003, 89:69-132.
126. Iha H., Kibler K.V., Yedavalli V.R., Peloponese J.M., Haller K., Miyazato A., et al. Segregation of NF-kappaB activation through NEMO/IKKgamma by Tax and TNFalpha: implications for stimulus-specific interruption of oncogenic signaling. Oncogene 2003, 22:8912-8923.
127. Pise-Masison C.A., Brady J.N. Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Frontiers Biosci J Virt Library 2005, 10:919-930.
128. Jeang K.T. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 2001, 12:207-217.
129. Jin D.Y., Spencer F., Jeang K.T. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998, 93:81-91.
130. Suzuki T., Kitao S., Matsushime H., Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J 1996, 15:1607-1614.
131. Hiscott J., Kwon H., Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 2001, 107:143-151.
132. Sun S.C., Ballard D.W. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. Oncogene 1999, 18:6948-6958.
133. Silva M.T., Mattos P., Alfano A., Araujo A.Q. Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls. J Neurol Neurosurg Psychiatry 2003, 74:1085-1089.
134. Gotuzzo E., Cabrera J., Deza L., Verdonck K., Vandamme A.M., Cairampoma R., et al. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis 2004, 39:939-944.
135. Kaplan J.E., Litchfield B., Rouault C., Lairmore M.D., Luo C.C., Williams L., et al. HTLV-I-associated myelopathy associated with blood transfusion in the United States: epidemiologic and molecular evidence linking donor and recipient. Neurology 1991, 41:192-197.
136. Yoshida Y., Machigashira N., Wang S.Y., Osame M. A patient with acute-onset HAM/TSP after blood transfusion complicated with pseudopseudohypoparathyroidism. Intern Med 2002, 41:899-900.
137. Gessain A. Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases. Bull Soc Pathol Exot 2011.
138. Nagai M., Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 2003, 9:228-235.
139. Afonso P.V., Ozden S., Cumont M.C., Seilhean D., Cartier L., Rezaie P., et al. Alteration of blood-brain barrier integrity by retroviral infection. PLoS Pathog 2008, 4:e1000205.
140. Lezin A., Olindo S., Oliere S., Varrin-Doyer M., Marlin R., Cabre P., et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis?. J Infect Dis 2005, 191:1830-1834.
141. Grassi M.F., Olavarria V.N., Kruschewsky Rde A., Mascarenhas R.E., Dourado I., Correia L.C., et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011, 83:1269-1274.
142. Lepoutre V., Jain P., Quann K., Wigdahl B., Khan Z.K. Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease. Front Biosci 2009, 14:1152-1168.
143. Barmak K., Harhaj E.W., Wigdahl B. Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003, 9:522-529.
144. La Grenade L., Manns A., Fletcher V., Derm D., Carberry C., Hanchard B., et al. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol 1998, 134:439-444.
145. Merle H., Cabre P., Olindo S., Merle S., Smadja D. Ocular lesions in 200 patients infected by the human T-cell lymphotropic virus type 1 in martinique (French West Indies). Am J Ophthalmol 2002, 134:190-195.
146. Nascimento M.C., Primo J., Bittencourt A., Siqueira I., de Fatima Oliveira M., Meyer R., et al. Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Clin Exp Immunol 2009, 156:455-462.
147. Primo J.R., Brites C., Oliveira Mde F., Moreno-Carvalho O., Machado M., Bittencourt A.L. Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clin Infect Dis 2005, 41:535-541.
148. Trojano M., Paolicelli D. The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. Neurol Sci 2001, 22(Suppl 2):S98-S102.
149. Fox R.I., Michelson P. Approaches to the treatment of Sjogren's syndrome. J Rheumatol Suppl 2000, 61:15-21.
150. Gudo E.S., Bhatt N.B., Bila D.R., Abreu C.M., Tanuri A., Savino W., et al. Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?. BMC Infect Dis 2009, 9:211.
151. Roy U., Simpson S.A., Mondal D., Eloby-Childress S., Winsor E.L., Beilke M.A. Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. J Med Virol 2008, 80:494-500.
152. Levin M.C., Rosenblum M.K., Fox C.H., Jacobson S. Localization of retrovirus in the central nervous system of a patient co-infected with HTLV-1 and HIV with HAM/TSP and HIV-associated dementia. J Neurovirol 2001, 7:61-65.
153. Solis M., Nakhaei P., Jalalirad M., Lacoste J., Douville R., Arguello M., et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol 2011, 85:1224-1236.
154. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-1407.
155. Yan N., Regalado-Magdos A.D., Stiggelbout B., Lee-Kirsch M.A., Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010, 11:1005-1013.
156. Datta A., Sinha-Datta U., Dhillon N.K., Buch S., Nicot C. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages. J Biol Chem 2006, 281:23414-23424.
157. Kerepesi L.A., Hess J.A., Leon O., Nolan T.J., Schad G.A., Abraham D. Toll-like receptor 4 (TLR4) is required for protective immunity to larval Strongyloides stercoralis in mice. Microbes Infect 2007, 9:28-34.
158. Braedel S., Radsak M., Einsele H., Latge J.P., Michan A., Loeffler J., et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol 2004, 125:392-399.
159. van de Veerdonk F.L., Teirlinck A.C., Kleinnijenhuis J., Kullberg B.J., van Crevel R., van der Meer J.W., et al. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 2010, 88:227-232.
160. Harvey R., Brown K., Zhang Q., Gartland M., Walton L., Talarico C., et al. GSK983: a novel compound with broad-spectrum antiviral activity. Antiviral Res 2009, 82:1-11.
161. Dimitrova D.I., Reichenbach N.L., Yang X., Pfleiderer W., Charubala R., Gaughan J.P., et al. Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B). AIDS Res Hum Retroviruses 2007, 23:123-134.
162. Satou Y., Nosaka K., Koya Y., Yasunaga J.I., Toyokuni S., Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004, 18:1357-1363.
163. Lezin A., Gillet N., Olindo S., Signate A., Grandvaux N., Verlaeten O., et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 2007, 110:3722-3728.